TWI917364B - Phd抑制劑化合物、組成物及使用方法 - Google Patents
Phd抑制劑化合物、組成物及使用方法Info
- Publication number
- TWI917364B TWI917364B TW110109983A TW110109983A TWI917364B TW I917364 B TWI917364 B TW I917364B TW 110109983 A TW110109983 A TW 110109983A TW 110109983 A TW110109983 A TW 110109983A TW I917364 B TWI917364 B TW I917364B
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- compound
- group
- halogen
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992616P | 2020-03-20 | 2020-03-20 | |
| US62/992,616 | 2020-03-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202140444A TW202140444A (zh) | 2021-11-01 |
| TWI917364B true TWI917364B (zh) | 2026-03-11 |
Family
ID=75478265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110109983A TWI917364B (zh) | 2020-03-20 | 2021-03-19 | Phd抑制劑化合物、組成物及使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12703691B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4121424A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7856575B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN120004851A (cg-RX-API-DMAC10.html) |
| AR (1) | AR121626A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TWI917364B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021188944A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| US12612367B2 (en) | 2019-12-10 | 2026-04-28 | Akebia Therapeutics, Inc. | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative |
| AR121626A1 (es) | 2020-03-20 | 2022-06-22 | Akebia Therapeutics Inc | Compuestos inhibidores de phd, composiciones y métodos de uso |
| JP2025500892A (ja) * | 2021-12-17 | 2025-01-15 | アケビア セラピューティクス インコーポレイテッド | 選択的phd1阻害剤化合物、組成物、及び使用方法 |
| CN118745146B (zh) * | 2024-06-24 | 2025-09-23 | 上海坦泰生物科技有限公司 | 一种5-氟-2-肼基吡啶二盐酸盐的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006114213A1 (de) | 2005-04-28 | 2006-11-02 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre verwendung 4- (pyridin-3-yl) -2- (pyridin-2-yl) -1,2-dihydro-3h-pyrazol-3-on derivate als spezifische hemmstoffe der hif-prolyl-4-hydroxylasen zur behandlung kardiovaskulärer und hämatologischer erkrankungen |
| WO2014160810A1 (en) | 2013-03-29 | 2014-10-02 | Takeda Pharmaceutical Company Limited | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663327A (en) * | 1984-05-23 | 1987-05-05 | Bayer Aktiengesellschaft | 1-heteroaryl-4-aryl-pyrazolin-5-ones |
| DE3443308A1 (de) * | 1984-11-28 | 1986-05-28 | Bayer Ag, 5090 Leverkusen | 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel |
| DE3527157A1 (de) | 1985-07-30 | 1987-02-12 | Bayer Ag | 1-heteroaryl-4-aryl-pyrazol-derivate |
| DE4023488A1 (de) | 1990-07-24 | 1992-01-30 | Bayer Ag | 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide |
| CA2138929A1 (en) | 1993-12-30 | 1995-07-01 | Klaus Weidmann | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals |
| CN102351791B (zh) | 2006-01-27 | 2014-10-29 | 菲布罗根有限公司 | 使低氧诱导因子(hif)稳定的氰基异喹啉化合物 |
| NZ623002A (en) | 2006-06-26 | 2015-08-28 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors and methods of use |
| US20090011051A1 (en) | 2006-09-28 | 2009-01-08 | Roth Mark B | Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds |
| DE102006050513A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substitiuierte Dihydropyrazolone und ihre Verwendung |
| DE102006050512A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte heterocyclische Verbindungen und ihre Verwendung |
| DE102006050516A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| DE102006050515A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| DE102007044032A1 (de) * | 2007-09-14 | 2009-03-19 | Bayer Healthcare Ag | Substituierte heterocyclische Verbindungen und ihre Verwendung |
| WO2010005851A1 (en) * | 2008-07-08 | 2010-01-14 | Xenon Pharmaceuticals Inc. | Combination therapy for treating iron disorders |
| SG172803A1 (en) | 2008-12-29 | 2011-08-29 | Sanofi Sa | Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators |
| NO2686520T3 (cg-RX-API-DMAC10.html) | 2011-06-06 | 2018-03-17 | ||
| WO2013134660A1 (en) | 2012-03-09 | 2013-09-12 | Fibrogen, Inc. | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
| US8987461B2 (en) * | 2012-12-06 | 2015-03-24 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| GB201504565D0 (en) | 2015-03-18 | 2015-05-06 | Takeda Pharmaceutical | Novel compounds |
| US11510917B2 (en) | 2016-02-19 | 2022-11-29 | Cornell University | HIF-stabilization and prevention of hyperoxia-induced neonatal lung disease |
| CN106831735B (zh) | 2017-01-23 | 2019-10-11 | 牡丹江医学院 | 一种治疗骨质疏松的杂环化合物及其制备方法和用途 |
| CN109879804B (zh) | 2019-01-30 | 2022-06-17 | 中国药科大学 | 5-杂环取代吡啶-2-甲酰甘氨酸化合物、其制法和医药用途 |
| EP4121425A1 (en) | 2020-03-20 | 2023-01-25 | Akebia Therapeutics Inc. | Phd inhibitor compounds, compositions, and use |
| KR20220156890A (ko) | 2020-03-20 | 2022-11-28 | 아케비아 테라퓨틱스 인코포레이티드 | Phd 억제제 화합물, 조성물, 및 용도 |
| AR121626A1 (es) | 2020-03-20 | 2022-06-22 | Akebia Therapeutics Inc | Compuestos inhibidores de phd, composiciones y métodos de uso |
| WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| EP4196466A1 (en) | 2020-08-14 | 2023-06-21 | Akebia Therapeutics Inc. | Phd inhibitor compounds, compositions, and methods of use |
-
2021
- 2021-03-19 AR ARP210100701A patent/AR121626A1/es unknown
- 2021-03-19 CN CN202510158546.8A patent/CN120004851A/zh active Pending
- 2021-03-19 WO PCT/US2021/023228 patent/WO2021188944A1/en not_active Ceased
- 2021-03-19 TW TW110109983A patent/TWI917364B/zh active
- 2021-03-19 CN CN202180034141.3A patent/CN115605467B/zh active Active
- 2021-03-19 JP JP2022556248A patent/JP7856575B2/ja active Active
- 2021-03-19 US US17/906,653 patent/US12703691B2/en active Active
- 2021-03-19 EP EP21718378.9A patent/EP4121424A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006114213A1 (de) | 2005-04-28 | 2006-11-02 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre verwendung 4- (pyridin-3-yl) -2- (pyridin-2-yl) -1,2-dihydro-3h-pyrazol-3-on derivate als spezifische hemmstoffe der hif-prolyl-4-hydroxylasen zur behandlung kardiovaskulärer und hämatologischer erkrankungen |
| WO2014160810A1 (en) | 2013-03-29 | 2014-10-02 | Takeda Pharmaceutical Company Limited | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202140444A (zh) | 2021-11-01 |
| US20230212138A1 (en) | 2023-07-06 |
| AR121626A1 (es) | 2022-06-22 |
| CN115605467A (zh) | 2023-01-13 |
| JP2023518543A (ja) | 2023-05-02 |
| CN115605467B (zh) | 2025-06-13 |
| CN120004851A (zh) | 2025-05-16 |
| EP4121424A1 (en) | 2023-01-25 |
| WO2021188944A1 (en) | 2021-09-23 |
| US12703691B2 (en) | 2026-08-11 |
| JP7856575B2 (ja) | 2026-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109810041B (zh) | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 | |
| JP7856575B2 (ja) | Phd阻害剤化合物、組成物、及びそれらの使用 | |
| EP3468956A1 (en) | 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists | |
| TWI912295B (zh) | Phd抑制劑化合物、組成物及使用方法 | |
| JP2026021443A (ja) | Phd阻害剤化合物、組成物、および使用 | |
| JP2005511602A (ja) | アントラニル酸アミドおよびvegf受容体チロシンキナーゼ阻害剤としてのその使用 | |
| JP7832179B2 (ja) | Phd阻害剤化合物、組成物、及び使用方法 | |
| BR122025027329A2 (pt) | Compostos, composição farmacêutica e uso | |
| TW202529740A (zh) | Phd抑制劑化合物、組成物及使用方法 | |
| CN118414327A (zh) | 作为选择性phd1抑制剂的吡啶酰胺化合物、组合物和使用方法 | |
| JP2024546944A (ja) | Rxfp1アゴニストとしてのナフタレンおよびキノリン類似体 |